Apr 02, 2025 | Pharmaceuticals & Healthcare
Pharma Pulse – February 2025: Growth Driven by Price and New Launches
India Ratings and Research (Ind-Ra) highlights that the Indian pharmaceutical market (IPM) delivered steady growth at 7.5% yoy in February 2025 (February 2024: 9.2% yoy; Source: Pharmatrac), on account of price growth (5.2% yoy) and new launches (2.4% yoy). However, volume growth (negative 0.2% yoy) remained weak during this period. Key therapies such as cardiac (9.5%), gastro (9.6%), central nervous system (CNS; 8.1%), and derma (8.3%) outperformed IPM growth, while respiratory (2.7%), gynaecology (2.2%), anti-infectives (4.3%), analgesic (6.5%), and anti-diabetic (6.0%) underperformed in February 2025. During April 2024 to February 2025, IPM on average grew 7.4% yoy (monthly) with volume growth at negative 0.8% yoy. Ind-Ra expects IPM to grow 8%-9% yoy in FY26 (FY24: 6.5% yoy; FY23: 9.9% yoy).